Will Canopy Growth’s Migration From NYSE to NASDAQ Mean Anything for Stock Investors?

Canopy Growth’s (TSX:WEED)(NYSE:CGC) move from the NYSE to the NASDAQ could bring small but incremental improvements to future earnings and cash flow.

| More on:
sad concerned deep in thought

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Canadian marijuana firm Canopy Growth (TSX:WEED)(NYSE:CGC) announced on Wednesday that it will move its U.S. stock listing from the New York Stock Exchange (NYSE) to the Nasdaq Global Select Market (NASDAQ). The transfer could happen after the market closes on Friday, November 13. Trade in WEED stock in the United States will resume under the same “CGC” ticker on NASDAQ on Monday.

Canopy Growth’s latest move follows a similar migration from the NYSE to the NASDAQ by industry peer Aphria (TSX:APHA)(NASDAQ:APHA) on May 31, this year. Like Aphria, Canopy cited cost savings as one of its main reasons for migrating to the NASDAQ.

How much could Canopy Growth’s save by moving stock from NYSE?

The New York Stock Exchange is arguably more prestigious for listed firms, but prestige comes at a cost. At times, the price paid for prestige can be significant, more so for a company struggling to break even.

The NYSE charges a minimum of US$71,000 or US$0.00113 per share in continued listing fees for 2020. Given Canopy’s 372,046,112 issued and outstanding shares balance, this quotation could translate to over US$420,000 ($554,000) per annum in continued listing costs.

On the other hand, the NASDAQ charges a minimum of US$46,000 in “all-inclusive” continued listing fees. Canopy Growth could expect to pay about US$159,000 in listing fees for 2020. This could translate into significant savings of over US$261,000 (about $345,000) per year.

Will the cost savings be significant for investors?

I estimated that Aphria could save more than $228,000 in annual listing expenses by shifting to the NASDAQ. The amount was about 4% of a previous quarter’s adjusted EBITDA.

The operating expense savings won’t be significant in Canopy Growth’s case. The savings represent under 0.4% of quarterly Adjusted EBITDA loss during the three months to June 2020.

Management is wise to continue reducing the leading cannabis firm’s operating expenses. The absolute number could be small for a company that spent over $304.6 million in general and administrative expenses during fiscal 2020.

However, the saving is being made on a cash expense. This will be significant to the company’s cash flow position and Adjusted EBITDA performance going forward. It’s a small but incremental step towards profitability. Given CGC’s ongoing struggle to contain operating costs and persistent operating losses, saving a third of a million dollars in annual operating expenses is a good idea.

Other proclaimed benefits

Management at Canopy Growth also claimed the company will gain access to a suite of investor relations services that “will help the company connect more efficiently” with current and future investors. It seems the company was referring to the NASDAQ’s investor intelligence suite, the Nasdaq IR Insight®.

Perhaps the NASDAQ has a superior product, but the NYSE has a somewhat similar investor relations offering.

Foolish bottom line

Any cost savings, however small, are good for business if they don’t negatively impact the firm’s reputation and its productivity. The company should continue to look for any areas for small incremental improvements. Investors will eventually take notice.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »